
Vividion Therapeutics and Bayer Expand Oncology Pipeline with Clinical-Stage WRN Inhibitor
Vividion Therapeutics and Bayer Strengthen Oncology Pipeline with Exclusive Rights to Clinical-Stage WRN Inhibitor VVD-214 Vividion Therapeutics, a clinical-stage biopharmaceutical company and a wholly owned, independently operated subsidiary of Bayer AG, announced today it has obtained exclusive global rights to…